Five weeks after the FDA approved a pill that extends survival in metastatic pancreatic cancer, one of the physicians who led ...

Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), and Acesion Pharma, a Copenhagen-based biotech company developing treatments for cardiac ...

Created by scientists for scientists, NEB prioritizes the advancement of science, stewardship of the environment, and giving back to the world around us in everything we do. Since our establishment in ...

MassBio is partnering with the ElevateBio team on November 2 to host 2026 R&D Reimagined – Techbio Solutions, the second in a ...

ODC Life Sciences is a specialized clinical research partner in Latin America, combining global clinical development ...

Absorption Systems is a preclinical contract research organization assisting pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, ...

SeraCare Life Sciences develops, manufactures, and sells a broad range of biological based materials and services essential for the manufacture of diagnostic tests, commercial bioproduction of ...

Sai Life Sciences is one of India’s fastest-growing full-service Contract Research, Development, and Manufacturing Organizations (CRDMOs). We partner with 300+ pharmaceutical and biotechnology ...

Global law firm Greenberg Traurig, LLP sponsored Kisaco Research’s IP Litigation North America Summit Sept. 14-16. The inaugural event brought together three dedicated industry tracks under one roof, ...

You’re invited to join PCI Pharma Services, Ypsomed and BD Pharmaceutical Systems ahead of PODD 2026 for Fireside Exchange, an exclusive evening bringing industry leaders together for candid ...

MassBio CEO & President Kendalle Burlin O’Connell originally posted this update to LinkedIn: This week, MassBio hosted our 2026 Align Summit, where policy and regulatory leaders joined industry ...

Developing complex oral therapies requires critical decisions at every stage, from navigating early formulation challenges and accelerating first-in-human studies to managing highly potent compounds ...